Help us develop a new cancer treatment

Professor Magnus Essand at Uppsala University has during six years developed and tested a potentially new treatment against neuroendocrine tumours. The treatment consists of an oncolytic virus, which has turned out to be remarkably efficient in destroying neuroendocrine tumours in mice.

With enough funding he will be able to start the world’s first human trials with a genetically engineered virus specifically designed to target neuroendocrine tumours.

You can help the research move forward by donating to the Oncolytic Virus Fund.

What if Antibiotics Stop Working?

Resistance to antibiotics is an enormous worldwide problem. Almost all bacteria will become resistant to today’s medicine, and within just a few years we will be faced with unimaginable setbacks, medically, socially and economically. Unless we act now.

It is our shared responsibility to ensure that current and future generations of people around the globe will have access to effective treatment of bacterial infections as part of their right to health. Working towards this goal means addressing both the problem of excess use to preserve the effect of existing antibiotics, but equally addressing the reverse problem of limited access in other settings to make sure these lifesaving medicines reach those who need them the most. We are facing a global problem that requires concerted action by all of us.

What is ReAct? ReAct is an independent global network for concerted action on antibiotic resistance based at Uppsala University. Learn more about ReAct here.

You can support ReAct through American Friends of Uppsala University. Please contact AFUU for further information about ways to give or donate online stating “ReAct” as your preferred choice.

Contributions to American Friends of Uppsala University are deductible by donors as provided by law. American Friends of Uppsala University is tax/exempt as a charitable organization by the Internal Revenue Service under section 501 (c) (3) of the Internal Revenue Code.